SKStephen Kravcik

Stephen Kravcik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Research Subjects


Stephen Kravcik has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • D. William Cameron

    Divisions of General Medicine and Infectious Diseases, Ottawa Hospital, General Campus, University of Ottawa , Ottawa, Ontario, Canada

    3 shared publications
  • Gary E. Garber

    Divisions of General Medicine and Infectious Diseases, Ottawa Hospital, General Campus, University of Ottawa , Ottawa, Ontario, Canada

    2 shared publications
  • Gary Victor

    Divisions of General Medicine and Infectious Diseases, Ottawa Hospital, General Campus, University of Ottawa , Ottawa, Ontario, Canada

    2 shared publications
  • Jonathan Benjamin Angel

    Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada

    2 shared publications
  • Nanci Hawley-Foss

    Department of Medicine, and

    2 shared publications
  • A Badley

    1 shared publication

Latest Publications

  • HIV Lipodystrophy: A Review

    by Stephen Kravcik

    The dramatic clinical benefit of highly active antiretroviral therapy has been offset, to an extent, by the development of unforeseen long-term toxicities. Of these, the HIV lipodystrophy syndrome is most prominent. The array of related but possibly separate manifestations includes fat deposition and atrophy and metabolic complications such as hyperlipidemias and diabetes mellitus. These have been attributed to the use of protease inhibitors, but other factors may be involved, particularly the use of nucleoside reverse transcriptase inhibitors, especially stavudine. The pathogenesis of any of the manifestations of the syndrome remains to be explained. The metabolic complications may respond to standard treatments, but most therapies directed at fat changes have been unsuccessful. This review will summarize the state of knowledge in the field.


  • Open Access

    Activity of the Combination of Nelfinavir and Saquinavir against Human Immunodeficiency Virus after Failure of Prior Protease Inhibitor Therapy

    by Gary E. Garber, Stephen Kravcik, Gary Victor, Jonathan B. Angel, Andrew D. Badley, D. William Cameron

    Stephen Kravcik, Gary Victor, Jonathan B. Angel, Andrew D. Badley, Gary E. Garber, D. William Cameron; Activity of the Combination of Nelfinavir and Saquinavir


    • 15 August 1999
      • Vol. 21  (5) , 371-5

    Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.

    by S Kravcik, K Gallicano, V Roth, S Cassol, N Hawley-Foss, A Badley, D W Cameron

    Combination antiretroviral therapy with ritonavir and saquinavir has established potent and durable activity on plasma viremia. CNS HIV infection may be sequestered from drug therapy that does not penetrate the blood-brain barrier. Penetration of these protease inhibitors into the cerebrospinal fluid (CSF) and CSF HIV RNA levels on such therapy has not been well described. In a cross-sectional study, 28 HIV1-infected study subjects were evaluated either before initiation of or before maximal response to ritonavir-saquinavir therapy, during maximal plasma virologic response, and after virologic failure. Simultaneous samples of plasma and cerebrospinal fluid were obtained from 24 study subjects to measure HIV RNA and protease inhibitor levels. Across the treatment groups, a strong correlation was found between plasma and CSF HIV RNA levels (r = 0.870; p < .001). In each study subject with plasma HIV RNA levels below assay limit (80 copies/ml), the CSF HIV RNA level was also below the limit of quantitation. Low levels of saquinavir (<2 ng/ml) and ritonavir (<25 ng/ml) in the CSF were observed, with a CSF:plasma drug concentration ratio of < or = 0.005 (0.5%) in all study subjects evaluated (n = 11). The plasma:CSF HIV RNA ratio was high before or early in treatment (median, 38; interquartile range [IQR], 13,97), but low (median, 0.29; IQR, 0.17, 7.5) in those failing therapy (group C, p < .001). CSF ritonavir and saquinavir levels are consistent with the estimated known fraction of unbound drug in plasma (<2%). Across these treatment response groups, suppression of plasma viremia can predict low CSF HIV RNA levels. This correlation may represent HIV RNA transport and equilibrium between CSF and plasma, or it may represent CNS anti-HIV activity of protease inhibitors. The low drug levels and inverted ratio of HIV RNA in the CSF compared with plasma early in plasma virologic breakthrough suggests CSF virologic failure may contribute to failure of plasma virologic response.


  • Cerebrospinal Fluid HIV RNA and Drug Levels With Combination Ritonavir and Saquinavir

    by Stephen Kravcik, Keith Gallicano, Virginia Roth, Sharon Cassol, Nanci Hawley-Foss, Andrew Badley, D. William Cameron

    Summary: Combination antiretroviral therapy with ritonavir and saquinavir has established potent and durable activity on plasma viremia. CNS HIV infection may be sequestered from drug therapy that does not penetrate the blood-brain barrier. Penetration of these protease inhibitors into the cerebrospinal fluid (CSF) and CSF HIV RNA levels on such therapy has not been well described. Design/Methods: In a cross-sectional study, 28 HIV-1-infected study subjects were evaluated either before initiation of or before maximal response to ritonavir-saquinavir therapy, during maximal plasma virologic response, and after virologic failure. Simultaneous samples of plasma and cerebrospinal fluid were obtained from 24 study subjects to measure HIV RNA and protease inhibitor levels. Results: Across the treatment groups, a strong correlation was found between plasma and CSF HIV RNA levels (r = 0.870; p < .001). In each study subject with plasma HIV RNA levels below assay limit (80 copies/ml), the CSF HIV RNA level was also below the limit of quantitation. Low levels of saquinavir (n = 11). The plasma:CSF HIV RNA ratio was high before or early in treatment (median, 38; interquartile range [IQR]. 13, 97), but low (median, 0.29; IQR, 0.17, 7.5) in those failing therapy (group C, p < .001). Conclusions: CSF ritonavir and saquinavir levels are consistent with the estimated known fraction of unbound drug in plasma (<2%). Across these treatment response groups, suppression of plasma viremia can predict low CSF HIV RNA levels. This correlation may represent HIV RNA transport and equilibrium between CSF and plasma, or it may represent CNS anti-HIV activity of protease inhibitors. The low drug levels and inverted ratio of HIV RNA in the CSF compared with plasma early in plasma virologic breakthrough suggests CSF virologic failure may contribute to failure of plasma virologic response.


  • Effect of Antiretroviral Therapy and Viral Load on the Perceived Risk of HIV Transmission and the Need for Safer Sexual Practices

    by Stephen Kravcik, Gary Victor, Sandra Houston, Donald Sutherland, Gary E. Garber, Nanci Hawley-Foss, Jonathan B. Angel, D. William Cameron

    Dramatic reductions in plasma HIV RNA levels are possible with current antiretroviral regimens; the effect of potent therapies and “undetectable” viral load on the perceived risk of HIV transmission and need for safer practices remains unknown. A questionnaire was developed to examine perceptions of HIV transmission risk and need for safer practices with unprotected anal, vaginal, and oral sex and intravenous drug use with needle sharing for HIV-discordant couples in which the HIV-infected partner was receiving no therapy, was receiving reverse transcriptase inhibitor therapy, and protease inhibitor (PI)-based therapy with viral load “undetectable”. This was applied anonymously to 147 unselected HIV-infected individuals attending a university-based HIV clinic. Almost all respondents believed that all sexual activities except oral sex were “very risky” and that safer practices were “extremely important” for those not receiving antiretroviral agents. Significantly fewer considered that anal or vaginal sex was “very risky” for those receiving PI therapy (90.9% and 86.0%, respectively), and fewer thought that safer practices for anal or vaginal sex were “very important” for those receiving PI therapy (93.0% and 91.6%, respectively). In total, 20.4% thought the risk of HIV transmission for at least one activity was reduced for those receiving PI therapy, and 19.0% believed that the need for safer practices was reduced by PI therapy. A small but significant proportion of HIV-infected people perceive the need for safer practices to be reduced during antiretroviral therapy, particularly those containing PIs. Even if the risk is truly reduced, the importance of safer practices should be conveyed consistently and terms such as “undetectable” to describe HIV RNA responses should be avoided.